^
BIOMARKER:

EGFR S768I

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/15/2021
Initiation :
10/22/2020
Primary completion :
09/01/2025
Completion :
09/01/2025
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
|
Avastin (bevacizumab) • Tagrisso (osimertinib) • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • Krabeva (bevacizumab biosimilar) • BP102 (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • HLX-04 (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase 1/2
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
10/04/2021
Initiation :
01/13/2015
Primary completion :
07/21/2025
Completion :
07/21/2025
MET
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR T790M negative
|
Tabrecta (capmatinib) • nazartinib (EGF816)
Phase 2
Duke University
Recruiting
Last update posted :
09/23/2021
Initiation :
06/30/2018
Primary completion :
06/30/2022
Completion :
06/30/2024
EGFR
|
EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
|
Tagrisso (osimertinib)
Phase 2
European Thoracic Oncology Platform
Recruiting
Last update posted :
09/09/2021
Initiation :
07/01/2020
Primary completion :
12/30/2022
Completion :
03/30/2023
EGFR
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR G719X • EGFR S768I
|
Avastin (bevacizumab) • carboplatin • Tecentriq (atezolizumab) • paclitaxel • pemetrexed
Phase 3
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Not yet recruiting
Last update posted :
07/07/2021
Initiation :
07/15/2021
Primary completion :
10/04/2023
Completion :
09/06/2024
EGFR
|
EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I
|
Ameile (almonertinib)
Phase 
Seoul St. Mary's Hospital
Active, not recruiting
Last update posted :
06/17/2021
Initiation :
02/24/2020
Primary completion :
12/17/2020
Completion :
09/30/2021
EGFR
|
EGFR mutation • EGFR L858R • EGFR L861Q • EGFR G719X • EGFR S768I
|
Gilotrif (afatinib) • Tagrisso (osimertinib)
Phase 2
Spectrum Pharmaceuticals, Inc
Recruiting
Last update posted :
06/15/2021
Initiation :
12/23/2019
Primary completion :
06/01/2023
Completion :
12/01/2023
EGFR
|
EGFR mutation • HER-2 amplification • EGFR L858R • EGFR T790M • HER-2 mutation • EGFR L861Q • HER-2 V777L • HER-2 exon 20 insertion • EGFR G719X • HER-2 S310F • EGFR S768I • EGFR E709K • HER-2 L869R • HER-2 V842I • EGFR P596L • EGFR R222C • HER-2 I655V • HER-2 T798M • EGFR E746 • HER-2 D769H • HER-2 R678Q • HER-2 T798I • HER-2 mutation + HER-2 T798I • EGFR V774M
|
poziotinib (HM 78136B)
Phase 2
Zhejiang Cancer Hospital
Recruiting
Last update posted :
06/11/2021
Initiation :
04/01/2021
Primary completion :
12/31/2021
Completion :
12/31/2021
BRAF • PD-L1 • KRAS
|
KRAS mutation • EGFR mutation • BRAF mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
|
Focus V (anlotinib) • Tyvyt (sintilimab)
Phase 1/2
Millennium Pharmaceuticals, Inc.
Recruiting
Last update posted :
05/25/2021
Initiation :
06/16/2016
Primary completion :
03/30/2022
Completion :
03/13/2023
EGFR • HER-2
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R
|
carboplatin • pemetrexed • Exkivity (mobocertinib)
Phase 1
Collin Blakely
Recruiting
Last update posted :
05/19/2021
Initiation :
11/12/2019
Primary completion :
05/31/2023
Completion :
05/31/2023
EGFR • TPX2
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L
|
Tagrisso (osimertinib) • alisertib (MLN8237)
Phase 2
Fondazione Ricerca Traslazionale
Recruiting
Last update posted :
05/07/2021
Initiation :
06/12/2020
Primary completion :
12/31/2023
Completion :
12/31/2023
EGFR • HER-2 • BRAF • ALK • MET • ROS1
|
EGFR mutation • BRAF mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion • ALK rearrangement • EGFR L861Q • ALK mutation • MET mutation • ROS1 rearrangement • EGFR G719S • EGFR S768I • EGFR G719A • EGFR G719C
|
Tagrisso (osimertinib) • Vizimpro (dacomitinib)
Phase 3
National Cancer Institute, Naples
Active, not recruiting
Last update posted :
03/05/2021
Initiation :
04/01/2016
Primary completion :
12/01/2021
Completion :
07/01/2022
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719S • EGFR S768I • EGFR G719A • EGFR G719C
|
Avastin (bevacizumab) • erlotinib
Phase 3
Millennium Pharmaceuticals, Inc.
Recruiting
Last update posted :
01/29/2021
Initiation :
01/06/2020
Primary completion :
06/30/2022
Completion :
11/30/2024
HER-2
|
EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
|
cisplatin • carboplatin • pemetrexed • Exkivity (mobocertinib)
Phase 2
Shanghai Chest Hospital
Recruiting
Last update posted :
01/05/2021
Initiation :
12/08/2020
Primary completion :
03/01/2022
Completion :
12/01/2022
EGFR
|
EGFR mutation • EGFR L858R • EGFR T790M • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L747P • EGFR exon 18 mutation • EGFR G719A • EGFR T854A • EGFR D761Y • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR L861R • EGFR R776H • EGFR G779C • EGFR R776C
|
Vizimpro (dacomitinib)
Phase 2
Intergroupe Francophone de Cancerologie Thoracique
Active, not recruiting
Last update posted :
04/24/2020
Initiation :
05/01/2016
Primary completion :
02/01/2019
Completion :
12/01/2020
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
|
Erbitux (cetuximab) • Gilotrif (afatinib)
Phase 2
Beijing Cancer Hospital
Recruiting
Last update posted :
07/17/2019
Initiation :
07/08/2019
Primary completion :
06/30/2020
Completion :
05/30/2021
EGFR • KRAS • ALK
|
KRAS mutation • EGFR mutation • ALK rearrangement • EGFR L861Q • EGFR G719X • EGFR S768I
|
Opdivo (nivolumab) • docetaxel
Phase N/A
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
05/21/2018
Initiation :
05/14/2015
Primary completion :
12/11/2017
Completion :
12/11/2017
EGFR
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR S768I • EGFR G719A • EGFR exon 19 insertion
|
erlotinib